Moderna Dives Despite Hard-Fought FDA Win; Will Its Sprint Restart?

Moderna (MRNA) stock wavered and slumped Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva. The approval comes after a lengthy battle with former FDA authorities. Previously, the FDA refused to review Moderna’s application, saying the study wasn’t “adequate or well controlled” and the standard flu shot it used in comparison didn’t reflect the…